The IPO market remained active this past week as seven IPOs raised $2.1 billion. SPAC activity kept steady with 10 blank check IPOs raising $1.6 billion. New filers continued to pour into the IPO pipeline, with 12 IPOs and nine SPACs submitting initial filings. ...read more
Lucid Diagnostics, which makes diagnostic tests for esophageal precancer and cancer, raised $70 million by offering 5 million shares at $14, the low end of the range of $14 to $16. Lucid is a commercial-stage medical diagnostics technology company focused on...read more
The Fall IPO market is expected to stay busy with eight IPOs schedule to raise $1.9 billion in the week ahead. Software development platform GitLab (GTLB) plans to raise $598 million at a $9.4 billion market cap. This founder-led company...read more
Lucid Diagnostics, which makes diagnostic tests for esophageal precancer and cancer, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint...read more
US IPO Weekly Recap: DevOps platform GitLab leads a 7 IPO week
The IPO market remained active this past week as seven IPOs raised $2.1 billion. SPAC activity kept steady with 10 blank check IPOs raising $1.6 billion. New filers continued to pour into the IPO pipeline, with 12 IPOs and nine SPACs submitting initial filings. ...read more
Medical diagnostics company Lucid Diagnostics prices IPO at $14 low end
Lucid Diagnostics, which makes diagnostic tests for esophageal precancer and cancer, raised $70 million by offering 5 million shares at $14, the low end of the range of $14 to $16. Lucid is a commercial-stage medical diagnostics technology company focused on...read more
US IPO Week Ahead: Software, payments, telecom towers, and more in an 8 IPO week
The Fall IPO market is expected to stay busy with eight IPOs schedule to raise $1.9 billion in the week ahead. Software development platform GitLab (GTLB) plans to raise $598 million at a $9.4 billion market cap. This founder-led company...read more
Medical diagnostics company Lucid Diagnostics sets terms for $75 million IPO
Lucid Diagnostics, which makes diagnostic tests for esophageal precancer and cancer, announced terms for its IPO on Thursday. The New York, NY-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. At the midpoint...read more